Completed PHASE3 INTERVENTIONAL 4-arm NCT03168256

CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis

A Phase 3 Randomized, Double-Blind, Placebo- and Active-Controlled Study of the Efficacy and Safety of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque Psoriasis

Sponsor: Can-Fite BioPharma

Conditions Plaque Psoriasis

Interventions Apremilast 30mg CF101 2mg CF101 3mg Placebo Oral Tablet

Updated 21 times since 2017 Last updated: Jun 27, 2022 Started: Sep 15, 2018 Primary completion: Jan 6, 2022 Completion: Apr 27, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Plaque Psoriasis, this trial is completed. The trial is conducted by Can-Fite BioPharma and has accumulated 21 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

21 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jul 2022 — Jul 2024 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Apr 2022 — Jul 2022 [monthly]

Active Not Recruiting PHASE3

▶ Show 16 earlier versions

Mar 2022 — Apr 2022 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Sep 2021 — Mar 2022 [monthly]

Recruiting PHASE3
Jun 2021 — Sep 2021 [monthly]

Recruiting PHASE3
Mar 2021 — Jun 2021 [monthly]

Recruiting PHASE3
Jan 2021 — Mar 2021 [monthly]

Recruiting PHASE3

Status: Active Not Recruiting → Recruiting
Apr 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Dec 2019 — Apr 2020 [monthly]

Recruiting PHASE3
Oct 2019 — Dec 2019 [monthly]

Recruiting PHASE3
Jul 2019 — Oct 2019 [monthly]

Recruiting PHASE3
Jun 2019 — Jul 2019 [monthly]

Recruiting PHASE3
Feb 2019 — Jun 2019 [monthly]

Recruiting PHASE3
Dec 2018 — Feb 2019 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Sep 2018 — Dec 2018 [monthly]

Not Yet Recruiting PHASE3
Jun 2018 — Sep 2018 [monthly]

Not Yet Recruiting PHASE3
May 2018 — Jun 2018 [monthly]

Not Yet Recruiting PHASE3
Jul 2017 — May 2018 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Can-Fite BioPharma

Data source: Can-Fite BioPharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Banja Luka, Bosnia and Herzegovina , Belgrade, Serbia , Bochnia, Poland , Brasov, Romania , Chisinau, Moldova , Gdansk, Poland , Haifa, Israel , Lodz, Poland , Mostar, Bosnia and Herzegovina , Niš, Serbia and 15 more locations